FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2114532112> ?p ?o ?g. }

• W2114532112 endingPage "A880" @default.
• W2114532112 startingPage "A880.1" @default.
• W2114532112 abstract "Background The role of rheumatoid factor (RF) and anti-cyclic citrullinated peptide antibodies (anti-CCP) in the response to treatment for rheumatoid arthritis (RA) is not fully understood. Studies investigating changes in the levels of RF in response to synthetic and biological DMARDs have not been able to confirm a definitive relationship between decreased RF subtypes and clinical response, while studies investigating changes in anti-CCP levels have yielded conflicting results. In addition, to our knowledge the correlation between autoantibodies and tocilizumab treatment has been poorly investigated. Objectives This study investigates the relationship between the presence and levels of RF and anti-CCP and clinical response to tocilizumab in patients with RA. Methods This was an observational longitudinal study in 27 patients with active, long-standing RA despite previous treatment with >2 DMARDs and/or steroids. Patients were treated with tocilizumab 8 mg/kg every 4 weeks. All patients were assessed using approved clinical scales (VES, PCR, HAQ, DAS28-VES, DAS28-PCR, CDAI, and SDAI). IgM-, IgA- and IgG-RFs and anti-CCP antibodies were assessed using ELISA at baseline, 3 months (T1), 6 months (T2), and 12 months (T3). Results All patients showed significant and sustained clinical response to tocilizmuab treatment. All clinical scales with the exception of HAQ significantly decreased. There was a significant correlation (p=0.03) between anti-CCP and SDAI changes from baseline at T1 and T2. Likewise there were no significant correlations between antibody count at T0 and changes in the DAS-28 VES at T1 and at T2. No significant relationship between clinical scales and antibody levels RF-IgG, IgA, IgM and anti-CCP levels were observed. Conclusions Tocilizumab is effective in treating the clinical symptoms of RA, and the efficacy of this molecule was not correlated with either RF or anti-CCP levels. There is now a growing body of evidence suggesting that markers associated with clinical response may not be the same biomarkers that predict risk of further joint damage References MIKULS TR, O’DELL JR, STONER JA, ET AL: Association of rheumatoid arthritis treatment response and disease duration with declines in serum levels of IgM rheumatoid factor and anti-cyclic citrullinated peptide antibody. Arthritis Rheum 2004; 50: 3776–82. KARSDAL MA, WOODWORTH T, HENRIKSEN K, ET AL: Biochemical markers of ongoing joint damage in rheumatoid arthritis--current and future applications, limitations and opportunities. Arthritis Res Ther 2011; 13: 215 TAKEUCHI T, TANAKA Y, AMANO K, ET AL: Clinical, radiographic and functional effectiveness of tocilizumab for rheumatoid arthritis patients-REACTION 52-week study. Rheumatology 2011; 50: 1908–15. Disclosure of Interest None Declared" @default.
• W2114532112 created "2016-06-24" @default.
• W2114532112 creator A5008521727 @default.
• W2114532112 creator A5009200286 @default.
• W2114532112 creator A5024547899 @default.
• W2114532112 creator A5028920471 @default.
• W2114532112 creator A5058563905 @default.
• W2114532112 creator A5063157066 @default.
• W2114532112 date "2013-06-01" @default.
• W2114532112 modified "2023-10-18" @default.
• W2114532112 title "AB0304 Clinical and serological response to tocilizumab in patients with rheumatoid arthritis" @default.
• W2114532112 doi "https://doi.org/10.1136/annrheumdis-2013-eular.2626" @default.
• W2114532112 hasPublicationYear "2013" @default.
• W2114532112 type Work @default.
• W2114532112 sameAs 2114532112 @default.
• W2114532112 citedByCount "2" @default.
• W2114532112 countsByYear W21145321122013 @default.
• W2114532112 countsByYear W21145321122018 @default.
• W2114532112 crossrefType "journal-article" @default.
• W2114532112 hasAuthorship W2114532112A5008521727 @default.
• W2114532112 hasAuthorship W2114532112A5009200286 @default.
• W2114532112 hasAuthorship W2114532112A5024547899 @default.
• W2114532112 hasAuthorship W2114532112A5028920471 @default.
• W2114532112 hasAuthorship W2114532112A5058563905 @default.
• W2114532112 hasAuthorship W2114532112A5063157066 @default.
• W2114532112 hasConcept C126322002 @default.
• W2114532112 hasConcept C159654299 @default.
• W2114532112 hasConcept C163764329 @default.
• W2114532112 hasConcept C198451711 @default.
• W2114532112 hasConcept C203014093 @default.
• W2114532112 hasConcept C23131810 @default.
• W2114532112 hasConcept C2776232647 @default.
• W2114532112 hasConcept C2777077863 @default.
• W2114532112 hasConcept C2777178219 @default.
• W2114532112 hasConcept C2777575956 @default.
• W2114532112 hasConcept C45189115 @default.
• W2114532112 hasConcept C71924100 @default.
• W2114532112 hasConcept C90924648 @default.
• W2114532112 hasConceptScore W2114532112C126322002 @default.
• W2114532112 hasConceptScore W2114532112C159654299 @default.
• W2114532112 hasConceptScore W2114532112C163764329 @default.
• W2114532112 hasConceptScore W2114532112C198451711 @default.
• W2114532112 hasConceptScore W2114532112C203014093 @default.
• W2114532112 hasConceptScore W2114532112C23131810 @default.
• W2114532112 hasConceptScore W2114532112C2776232647 @default.
• W2114532112 hasConceptScore W2114532112C2777077863 @default.
• W2114532112 hasConceptScore W2114532112C2777178219 @default.
• W2114532112 hasConceptScore W2114532112C2777575956 @default.
• W2114532112 hasConceptScore W2114532112C45189115 @default.
• W2114532112 hasConceptScore W2114532112C71924100 @default.
• W2114532112 hasConceptScore W2114532112C90924648 @default.
• W2114532112 hasIssue "Suppl 3" @default.
• W2114532112 hasLocation W21145321121 @default.
• W2114532112 hasOpenAccess W2114532112 @default.
• W2114532112 hasPrimaryLocation W21145321121 @default.
• W2114532112 hasRelatedWork W1838548883 @default.
• W2114532112 hasRelatedWork W189077404 @default.
• W2114532112 hasRelatedWork W1979392798 @default.
• W2114532112 hasRelatedWork W1987294331 @default.
• W2114532112 hasRelatedWork W2162218521 @default.
• W2114532112 hasRelatedWork W2953955431 @default.
• W2114532112 hasRelatedWork W2996380604 @default.
• W2114532112 hasRelatedWork W3009536542 @default.
• W2114532112 hasRelatedWork W3012989600 @default.
• W2114532112 hasRelatedWork W4239841759 @default.
• W2114532112 hasVolume "72" @default.
• W2114532112 isParatext "false" @default.
• W2114532112 isRetracted "false" @default.
• W2114532112 magId "2114532112" @default.
• W2114532112 workType "article" @default.